(Circulation. 2008;117:1594-1602.)
© 2008 American Heart Association, Inc.
Basic Science for Clinicians |
From the Institute for Molecular Cardiovascular Research (A.Z., C.W.) and Department of Biochemistry and Molecular Cell Biology (J.B.), Molekulare Herz-Kreislaufforschung, RWTH Aachen University, Aachen, Germany.
Correspondence to Dr Christian Weber, Institut für Molekulare Herz-Kreislaufforschung, Universitätsklinikum der RWTH Aachen, Pauwelsstraβe 30, 52074 Aachen, Germany (e-mail cweber{at}ukaachen.de); or Dr Jürgen Bernhagen, Institut für Biochemie, Universitätsklinikum der RWTH Aachen, Pauwelsstraβe 30, 52074 Aachen, Germany (e-mail jbernhagen@ukaachen.de).
The highly conserved and archetypical yet atypical cytokine macrophage migration inhibitory factor (MIF) fulfills pleiotropic immune functions in many acute and chronic inflammatory diseases. Recent evidence has emerged from both expression and functional studies to implicate MIF in various aspects of cardiovascular disease. The present review is aimed at providing a synopsis of the involvement of MIF in the inflammatory pathogenesis of atherosclerosis and its consequences, namely unstable plaque formation, remodeling after arterial injury, aneurysm formation, myocardial infarction, or ischemia-reperfusion injury. In addition, other forms of myocardial dysfunction and inflammation and the role of MIF in angiogenesis are reviewed. The functional data are reconciled with recent progress in the identification of heptahelical (CXC chemokine) receptors for MIF, its prototypic role as their noncanonical ligand, and its signal transduction profile operative in atherogenic and inflammatory recruitment of mononuclear cells and in the oxidative damage and apoptosis of cardiomyocytes. Its unique features and functions clearly distinguish MIF from other cytokines implicated in atherogenesis and make it a prime target for achieving therapeutic regression of atherosclerosis. The potential of targeting or exploiting MIF for therapeutic strategies or as a diagnostic marker in the management of cardiovascular diseases or disorders is scrutinized.
Key Words: atherosclerosis cytokines inflammation myocardium remodeling
This article has been cited by other articles:
![]() |
L. Verschuren, T. Kooistra, J. Bernhagen, P. J. Voshol, D. M. Ouwens, M. van Erk, J. de Vries-van der Weij, L. Leng, J. H. van Bockel, K. W. van Dijk, et al. MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the Development of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease Circ. Res., July 2, 2009; 105(1): 99 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, O. Zis, G. Ma, Z. Shan, X. Zhang, S. Wang, C. Dai, J. Zhao, Q. Lin, S. Lin, et al. Upregulation of Macrophage Migration Inhibitory Factor Gene Expression in Stroke Stroke, March 1, 2009; 40(3): 973 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zernecke, E. Shagdarsuren, and C. Weber Chemokines in Atherosclerosis: An Update Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1897 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Weber, S. Kraemer, M. Drechsler, H. Lue, R. R. Koenen, A. Kapurniotu, A. Zernecke, and J. Bernhagen Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment PNAS, October 21, 2008; 105(42): 16278 - 16283. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |